Abstract:In recent study, in order to improve the bioavailability of endomorphin-1 (EM-1), we designed and synthesized a series of novel EM-1 analogs by replacement of L-Pro2 by β-Pro, D-Ala or Sar, together with C-terminal oligoarginine-conjugation. Our results indicated that the introduction of D-Ala and β-Pro in position 2, along with oligoarginine-conjugation, didn't significantly decrease the μ-affinity and in vitro bioactivity, and the enhancement of arginine residues did not markedly influence the μ-affinity of these analogs. All analogs displayed a significant enhancement of stability, which may be due to increased resistance to proline-specific enzymatic degradation. Moreover, following intracerebroventricular (i.c.v.) administration, analogs 1, 2, 4 and 5 produced significant antinociception and increased duration of action, with the ED50 values being about 1.8- to 4.2-fold less potent than that of EM-1. In addition, our results indicated that no significant antinociceptive activity of EM-1 was seen following subcutaneous (s.c.) injection, whereas analogs 1, 2, 4 and 5 with equimolar dose induced significant and prolonged antinociception by an opioid and central mechanism. Herein, we further examined the gastrointestinal transit and colonic propulsive latencies of EM-1 and its four analogs administered centrally and peripherally. I.c.v. administration of EM-1 and analogs 1, 2, 4 and 5 significantly delayed gastrointestinal transit and colonic bead propulsion in mice, but the inhibitory effects induced by these analogs were largely attenuated. It is noteworthy that no significant gastrointestinal side effects induced by these four analogs were observed after s.c. administration. Our results demonstrated that combined modifications of EM-1 with unnatural amino acid substitutions and oligoarginine-conjugation gave an efficient strategy to improve the analgesic profile of EM-1 analogs but with less gastrointestinal side effects when administered peripherally.

Contribution of the μ opioid receptor and enkephalin to the antinociceptive actions of endomorphin-1 analogs with unnatural amino acid modifications in the spinal cord

Structure-Constrained Endomorphin Analogs Display Differential Antinociceptive Mechanisms in Mice after Spinal Administration

The spinal anti-allodynic effects of endomorphin analogs with C-terminal hydrazide modification in neuropathic pain model

Synthesis and Antinociceptive Effects of Endomorphin-1 Analogs with C-terminal Linked by Oligoarginine

The Spinal Antinociceptive Effects of Endomorphins in Rats: Behavioral and G Protein Functional Studies

Endomorphin-2 Analogs with C-terminal Esterification Display Potent Antinociceptive Effects in the Formalin Pain Test in Mice.

Differential Antinociceptive Effects of Intrathecal Administration of C‐terminal Esterified Endomorphin‐2 Analogues in Mice

Novel Endomorphin Analogues CEMR-1 and CEMR-2 Produce Potent and Long-Lasting Antinociception with a Favourable Side Effect Profile at the Spinal Level

Endomorphin-1 Analogs with Oligoarginine-Conjugation at C-terminus Produce Potent Antinociception with Reduced Opioid Tolerance in Paw Withdrawal Test.

Design, Synthesis, and Evaluation of New Endomorphin Analogs with Enhanced Central Antinociception after Peripheral Administration.

Design, Synthesis, and Biological Activity of New Endomorphin Analogs with Multi-Site Modifications

Novel endomorphin-1 analogs with C-terminal oligoarginine-conjugation display systemic antinociceptive activity with less gastrointestinal side effects.

Mechanism Underlying the Analgesic Effect Exerted by Endomorphin-1 in the Rat Ventrolateral Periaqueductal Gray

Endomorphin-2 Analogs with C-terminal Esterification Produce Potent Systemic Antinociception with Reduced Tolerance and Gastrointestinal Side Effects

Novel endomorphin analogs CEMR‐1 and CEMR‐2 produce potent and long‐lasting antinociception with a favorable side effect profile at the spinal level

Endomorphins: Promising Endogenous Opioid Peptides for the Development of Novel Analgesics

MEL-N16: A Series of Novel Endomorphin Analogs with Good Analgesic Activity and a Favorable Side Effect Profile

Endomorphin-1 Analogs Containing Α-Methyl-β-amino Acids Exhibit Potent Analgesic Activity after Peripheral Administration.

In vitro and in vivo characterization of opioid activities of endomorphins analogs with novel constrained C-terminus: evidence for the important role of proper spatial disposition of the third aromatic ring.

Novel Cyclic Endomorphin Analogues with Multiple Modifications and Oligoarginine Vector Exhibit Potent Antinociception with Reduced Opioid-like Side Effects

In Vitro and in Vivo Characterization of Opioid Activities of C-terminal Esterified Endomorphin-2 Analogs